Results 31 to 40 of about 1,482 (173)

Successful treatment of alopecia universalis with abrocitinib: a case report

Journal of Dermatological Treatment, 2023
Abrocitinib, a highly selective inhibitor of Janus kinase 1 (JAK1), has been approved for the treatment of moderate-to-severe atopic dermatitis (AD).
Jie- Zhang, Ya-Gang Zuo
doaj   +1 more source

Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark

Acta Dermato-Venereologica
The emergence of new systemic treatments for alopecia areata underscores the importance of estimating rates of potential treatment safety events among individuals with alopecia areata.
Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, Robert Wolk, Lynne Napatalung, Samuel H. Zwillich, Lars Iversen, Vera Ehrenstein   +7 more
doaj   +1 more source

Effective management Alopecia totalis by Ayurveda – A case report

Journal of Ayurveda and Integrative Medicine, 2023
Alopecia areata (AA) is a T-cell-mediated autoimmune illness characterized by intermittent, non-scarring hair loss, Alopecia totalis(AT) is a type of AA characterized by total hair loss on the face and scalp.
Shivanand B. Patil, Giramalla S. Patil, Vijay Patil   +2 more
doaj   +1 more source

Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib

Frontiers in Medicine, 2023
Alopecia areata (AA) is a non-scarring hair loss disorder. Alopecia totalis (AT) and alopecia universalis (AU) are the severe subtypes of AA. Age of onset before 6 years of age, disease duration of more than 1 year, and extensive alopecia involving more ...
Lu Cai, Lu Cai, Yi Wei, Min Zhao, Jia Zhuo, Xiao Tao, Mao Lin, Mao Lin   +7 more
doaj   +1 more source

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Scale of Alopecia Areata Distress (SAAD‐41): Initial Validation Part 2—Scoring, Preliminary Reference Values and Validity

JEADV Clinical Practice, EarlyView.
The SAAD‐41 is a 41‐item scale developed to comprehensively assess Alopecia Areata psychosocial patient‐reported outcomes. Results support scoring the scale at the subdomain level and provisionally at the total‐score level. The total‐score can be calculated as a sum of the 41 SAAD items, with the sum referred to as the SAAD‐41‐Total.
Kristina Gorbatenko‐Roth, Mattea Trinitapoli, Sarah Wood, Irmina Wallander, Jaime Nugent, Maria Hordinsky   +5 more
wiley   +1 more source

Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross‐Sectional Survey Study

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives To estimate the lifetime and point prevalence of alopecia areata (AA) among Australians aged ≥ 15 years. Methods A cross‐sectional survey was conducted from August to September 2024 in a quota‐balanced sample of the Australian population, aged ≥ 12 years (exploratory objective included participants aged 12–14 years ...
Rodney Sinclair, Samantha Eisman, Leona Yip, Maureen Hitschfeld, Anna Williamson, Giles Stratton, Christoph Lohan, Carol M. Y. Lee, Komal Kapoor, Candida da Fonseca Pereira   +9 more
wiley   +1 more source

Non‐Invasive Scalp Tape‐Strip RNA Sequencing Captures Disease Activity and Treatment‐Response Signatures in Alopecia Areata

Allergy, EarlyView.
Non‐invasive scalp tape‐strip RNA sequencing captures core immune and follicular molecular signatures in alopecia areata. Tape‐strip transcriptomic profiles reflect disease severity and treatment response to baricitinib, with concordance to scalp biopsy‐derived signatures.
Carmen Mochón‐Jiménez, Jesús Gay‐Mimbrera, Viviana Dávila‐Flores, Helen He, Jerry Zhou, Irene Rivera‐Ruiz, Pedro J. Gómez‐Arias, Juan de Luque‐Fernández, Benjamin Ungar, Emma Guttman‐Yassky, Juan Ruano   +10 more
wiley   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

Clinical &Experimental Allergy, EarlyView.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia   +11 more
wiley   +1 more source

Hypnose bij patiënten met alopecia areata, areata totalis en alopecia universalis – gedeeltelijke of totale kaalhoofdigheid [PDF]

Dth, 2002
Na een samenvatting van de etiologie en de mogelijke psychotherapeutische behandeling van alopecia areata en alopecia universalis, beschrijven we aan de hand van casuistiek de hypnotherapeutische aanpak bij de behandeling van gedeeltelijke of volledige kaalheid. Vervolgens presenteren we de resultaten van de hypnosebehandeling bij zestien patienten met
Willemsen, Maria, Vanderlinden, Johan, Roseeuw, Diane   +2 more
openaire   +2 more sources